NCT03063034

CSD1602: A Crossover Study to Evaluate the Exposure to "Tar" and Nicotine From Two King Size Menthol Cigarette Products

Completed NA Last updated 14 March 2017

What this trial tests

NA trial testing PD21864AA in Smoking in 39 participants. Completed in 13 March 2017.

Timeline

6 February 2017

Primary endpoint
13 March 2017

13 March 2017

Quick facts

Lead sponsor	RAI Services Company
Phase	NA
Status	Completed
Study type	INTERVENTIONAL
Allocation	randomized
Design	crossover
Masking	none
Primary purpose	other
Enrollment	39
Start date	6 February 2017
Primary completion	13 March 2017
Estimated completion	13 March 2017
Sites	1 location across United States

Drugs / interventions tested

• PD21864AA
• PD21864AB

Conditions studied

• Smoking — all drugs for Smoking →

Sponsor

RAI Services Company

Who can join

21 and older, any sex, with Smoking. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

This study will evaluate exposure to "tar" and nicotine from two menthol cigarette products and provide a basis for comparing mouth-level exposure when smokers smoke the two cigarette products. Mouth-level exposure is the measurement of substance trapped in the cigarette butt after smoking the cigarette.

Other purposes of this study are to:

* Compare the plasma cotinine, a byproduct of your body's processing of nicotine, levels found in users after smoking each of two different cigarettes.
* Find out the daily mouth-level exposure to cigarette "tar" and nicotine from smoking each of two different cigarettes in adult smokers.
* Determine if certain measures of nicotine dependence change based on the type of cigarette smoked
* To compare product liking and intent to use it again.

Publications & conference data

No peer-reviewed publications indexed yet for this trial. Completed trials usually publish results within 12-18 months.